MX2010000693A - Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para establilizar el compuesto. - Google Patents
Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para establilizar el compuesto.Info
- Publication number
- MX2010000693A MX2010000693A MX2010000693A MX2010000693A MX2010000693A MX 2010000693 A MX2010000693 A MX 2010000693A MX 2010000693 A MX2010000693 A MX 2010000693A MX 2010000693 A MX2010000693 A MX 2010000693A MX 2010000693 A MX2010000693 A MX 2010000693A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- deoxy
- pharmaceutical composition
- stabilizing
- prostaglandin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
Se proporciona una composición farmacéutica que comprende un compuesto de 11-desoxi-prostaglandina representado por la fórmula (I): y un éster de ácido graso; mezclando el compuesto de fórmula (I) y un éster de ácido graso, el compuesto de fórmula (I) se estabilizará.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92994807P | 2007-07-19 | 2007-07-19 | |
PCT/JP2008/063222 WO2009011449A2 (en) | 2007-07-19 | 2008-07-16 | Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2010000693A true MX2010000693A (es) | 2010-06-01 |
MX339727B MX339727B (es) | 2016-06-06 |
Family
ID=39720491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010000693A MX339727B (es) | 2007-07-19 | 2008-07-16 | Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para estabilizar el compuesto. |
Country Status (14)
Country | Link |
---|---|
US (2) | US8969324B2 (es) |
EP (2) | EP2327398A3 (es) |
JP (2) | JP5390519B2 (es) |
KR (1) | KR101485212B1 (es) |
CN (2) | CN101808623B (es) |
AU (1) | AU2008276840B2 (es) |
BR (1) | BRPI0814115B8 (es) |
CA (1) | CA2691995C (es) |
IL (1) | IL203064B (es) |
MX (1) | MX339727B (es) |
NZ (2) | NZ595270A (es) |
RU (3) | RU2506072C2 (es) |
TW (2) | TWI446912B (es) |
WO (1) | WO2009011449A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2420291C3 (ru) * | 2006-01-24 | 2020-07-21 | Р-Тек Уено, Лтд. | Состав в мягкой желатиновой капсуле |
BR112014002712A8 (pt) * | 2011-08-05 | 2017-06-20 | Sucampo Ag | método para tratamento da esquizofrenia |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
JP6580414B2 (ja) * | 2015-08-07 | 2019-09-25 | 小林製薬株式会社 | 生薬末含有錠剤 |
US10716544B2 (en) | 2015-10-08 | 2020-07-21 | Zmk Medical Technologies Inc. | System for 3D multi-parametric ultrasound imaging |
CN108619107A (zh) * | 2018-05-28 | 2018-10-09 | 青海制药厂有限公司 | 一种含鲁比前列酮的软胶囊及其制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE572839A (es) * | 1958-02-12 | |||
JPS5350141A (en) * | 1976-10-18 | 1978-05-08 | Ono Pharmaceut Co Ltd | Stabilization of prostaglandin and prostaglandin analogues |
US4310543A (en) * | 1980-10-09 | 1982-01-12 | Hoffmann-La Roche Inc. | Prostaglandin compositions |
US4301175A (en) * | 1980-12-29 | 1981-11-17 | The Upjohn Company | E-Type prostaglandin compositions |
US4431833A (en) * | 1982-12-27 | 1984-02-14 | American Cyanamid Company | Prostaglandin and hydroxylated fatty acid ester formulations |
KR920007569B1 (ko) * | 1984-11-30 | 1992-09-07 | 쥬우가이 세이야꾸 가부시끼가이샤 | 프로스타글란딘 e 유도체의 안정한 제제의 제조방법 |
US5166174A (en) * | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
US6183466B1 (en) * | 1998-08-21 | 2001-02-06 | Alza Corporation | Dosage form comprising a capsule |
DE60039727D1 (de) * | 1999-10-15 | 2008-09-11 | Sucampo Ag | Neue Zusammensetzung enthaltend eine bicyclische Verbindung und ein Glycerid |
JP4995407B2 (ja) * | 2002-04-25 | 2012-08-08 | バナー ファーマキャップス, インコーポレーテッド | 咀嚼可能なソフトカプセル |
FR2850275B1 (fr) * | 2003-01-24 | 2005-04-08 | Scherer Technologies Inc R P | Capsules molles a macher contenant une substance active a gout masque |
ATE402759T1 (de) * | 2004-02-17 | 2008-08-15 | Symrise Gmbh & Co Kg | Überzogene, sphärische, nahtlose, gefüllte kapseln |
NZ556710A (en) * | 2005-01-27 | 2010-08-27 | Sucampo Ag | Method and composition for treating central nervous system disorders |
ATE489955T1 (de) * | 2005-03-04 | 2010-12-15 | Sucampo Ag | Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten |
RU2420291C3 (ru) * | 2006-01-24 | 2020-07-21 | Р-Тек Уено, Лтд. | Состав в мягкой желатиновой капсуле |
-
2008
- 2008-07-16 NZ NZ59527008A patent/NZ595270A/xx not_active IP Right Cessation
- 2008-07-16 JP JP2010516705A patent/JP5390519B2/ja not_active Expired - Fee Related
- 2008-07-16 WO PCT/JP2008/063222 patent/WO2009011449A2/en active Application Filing
- 2008-07-16 KR KR1020107003612A patent/KR101485212B1/ko active IP Right Grant
- 2008-07-16 MX MX2010000693A patent/MX339727B/es active IP Right Grant
- 2008-07-16 NZ NZ583203A patent/NZ583203A/en not_active IP Right Cessation
- 2008-07-16 US US12/174,230 patent/US8969324B2/en active Active
- 2008-07-16 CA CA2691995A patent/CA2691995C/en active Active
- 2008-07-16 EP EP20110158821 patent/EP2327398A3/en not_active Withdrawn
- 2008-07-16 AU AU2008276840A patent/AU2008276840B2/en not_active Ceased
- 2008-07-16 EP EP08778342.9A patent/EP2178516B1/en not_active Not-in-force
- 2008-07-16 CN CN2008800250368A patent/CN101808623B/zh not_active Expired - Fee Related
- 2008-07-16 RU RU2010105847/15A patent/RU2506072C2/ru active
- 2008-07-16 CN CN2013102926965A patent/CN103393618A/zh active Pending
- 2008-07-16 BR BRPI0814115A patent/BRPI0814115B8/pt active IP Right Grant
- 2008-07-17 TW TW97127090A patent/TWI446912B/zh not_active IP Right Cessation
- 2008-07-17 TW TW103122235A patent/TWI552772B/zh not_active IP Right Cessation
-
2009
- 2009-12-31 IL IL203064A patent/IL203064B/en active IP Right Grant
-
2013
- 2013-07-26 RU RU2013135403A patent/RU2651471C2/ru active
- 2013-10-09 JP JP2013211759A patent/JP2014001247A/ja active Pending
-
2015
- 2015-01-06 US US14/590,067 patent/US9254326B2/en not_active Expired - Fee Related
-
2018
- 2018-04-12 RU RU2018113296A patent/RU2018113296A/ru not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ592497A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
GEP20135919B (en) | Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors | |
GEP20146102B (en) | Compounds and compositions as protein kinase inhibitors | |
EG25480A (en) | Method for preparation of optionally 2-substituted1,6-dihydro-6-oxo-4-pyrimidinecarboxylic acids | |
TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
CA2757418C (en) | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same | |
TN2009000249A1 (en) | Mapk/erk kinase inhibitors | |
MX2011010415A (es) | Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. | |
AU2009310099A8 (en) | Agricultural compositions | |
MX2010000693A (es) | Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para establilizar el compuesto. | |
ME00680B (me) | Nova jedinjenja diozmetina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže | |
CY1115623T1 (el) | Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ | |
AU2010356056A8 (en) | Phosphoric acid ester compound of hydroxy acid substituted phenyl ester, synthesis method and medical use thereof | |
TW200612959A (en) | Method for preparing hydroxamic acids | |
PT2462098E (pt) | Processos para a preparação de derivados de ácido 1-(2- halobifenil-4-il)-ciclopropanocarboxílico | |
MX2010009926A (es) | Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico. | |
WO2011047055A8 (en) | Novel mek inhibitors, useful in the treatment of diseases | |
NZ598278A (en) | Process for preparing biphenyl imidazole compounds | |
TNSN08531A1 (en) | Phenylacetic acid derivatives as cox - 2 inhibitors | |
GEP20125563B (en) | 2-amino-2-phenylalkanol derivatives, preparation method thereof and pharmaceutical compositions containing same | |
TW200738703A (en) | 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof | |
MY180567A (en) | Arylcyclopropylacetamide derivatives useful as glucokinase activators | |
WO2011031764A3 (en) | Compounds and related methods of use | |
UA101419C2 (ru) | Композиция и способ для борьбы с болезнями растений | |
NZ589911A (en) | Styrylbenzofuran derivatives as inhibitors for beta-amyloid fibril formation and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |